Sargramostim

Drug Profile

Sargramostim

Alternative Names: BI 61012; GZ 402664; Interberin; Leukine; Leukine Liquid; Prokine; Recombinant human GM‑CSF; rhuGM-CSF

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Bayer HealthCare Pharmaceuticals Inc.; Cincinnati Children's Hospital Medical Center; National Institute on Aging; Sanofi Genzyme; University of California at Irvine; University of California at San Francisco; University of Colorado at Denver; University of Texas M. D. Anderson Cancer Center; Virginia Commonwealth University
  • Class Adjuvants; Chemoprotectants; Granulocyte-macrophage colony-stimulating factors
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Macrophage stimulants; Neutrophil stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bone marrow disorders; Neutropenia; Pneumococcal infections; Stem cell mobilisation
  • Phase II Alzheimer's disease; Chronic lymphocytic leukaemia; Prostate cancer; Pulmonary alveolar proteinosis
  • Clinical Phase Unknown Acute radiation syndrome
  • No development reported Malignant melanoma; Ovarian cancer
  • Discontinued Crohn's disease; Follicular lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 16 Jul 2017 Interim efficacy and adverse events data from a phase II safety and efficacy trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
  • 16 Jul 2017 Alzheimer’s Association plans a clinical trial for Alzheimer’s disease
  • 16 Jul 2017 University of Colorado initiates enrolment in a phase II pilot safety and efficacy trial for Alzheimer's disease in USA before July 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top